We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Horizon Pharma Gets FDA Nod for Procysbi Label Expansion
Read MoreHide Full Article
Horizon Pharma plc announced that the FDA has approved the label expansion for Procysbi (cysteamine bitartrate) delayed-release capsules. The label will include children aged one year and above suffering from nephropathic cystinosis.
Procysbi is a delayed-release form of cysteamine bitartrate that works by continuously reducing the toxic concentration of cystine in the cells. It plays an important role in managing nephropathic cystinosis and is already approved for both the adults and minors as young as two year-olds.
Horizon’s shares have underperformed the industry year to date. The stock has declined 7.2% against the industry’s growth of 3.5%.
The company’s receipt of the approval for Procysbi’slabel expansion was based on a study that enrolled 17 patients living with nephropathic cystinosis including 15 kids aged between one and five years, previously not treated with cysteamine therapy. The children experienced low white blood cell (WBC) cystine levels varying from poorly to well controlled stages at 12 and 18-month measurements. WBC levels are the biomarker for disease control. . Also a marked improvement was noticed in their weight and height. The study was performed per the FDA’s requirement as a post-marketing commitment after Procysbi was approved.
The Procysbi prescribing information now contains an amended guidance for physicians administering the medicine to pediatric patients.
We remind investors that the ex-U.S. right to Procysbi was divested by Horizon. In May, the company had signed an agreement with Chiesi Farmaceutici S.p.A. to sell its European subsidiary — owning the marketing rights to Procysbi delayed-release capsules — and Quinsair (levofloxacin inhalation solution) in Europe, the Middle East and Africa (EMEA) regions.
Notably, both Procysbi and Quinsair were added in Horizon’s portfolio courtesy of the acquisition of Raptor Pharmaceutical Corp. in October 2016. This strategic transaction happened to strengthen Horizon’s orphan business in the United States and expand its footprint in Europe as well as in other key international markets.
However, following an evaluation of the commercial infrastructure, needed to make Procysbi and Quinsair available across the EMEA belt, the company decided to divest the rights in Europe.
Horizon carries a Zacks Rank #3 (Hold). Some better-ranked health care stocks in the same space are Sucampo Pharmaceuticals , Achillion Pharmaceuticals, Inc. and Corcept Therapeutics Incorporated (CORT - Free Report) , all carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Sucampo’s earnings per share estimates have moved up from 31 cents to $1.12 for 2017 and from $1.15 to $1.19 for 2018 in the last 30 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 15.63%. Share price of the company has surged 32.6% year to date.
Achillionhas seen the Zacks Consensus Estimate of current-year loss per share being narrowed from 65 cents to 63 cents and from 74 cents to 67 cents for 2018 in the last 60 days. The company came up with positive earnings surprises in two of the last four quarters with an average beat of 4.51%.
Corcept’s earnings per share estimates have been revised upward from 78 cents to 88 cents for 2018 in the last 60 days. The company pulled off positive earnings surprises in two of the trailing four quarters with an average beat of 14.32%. Shares of the company have skyrocketed 142.7% year to date.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Horizon Pharma Gets FDA Nod for Procysbi Label Expansion
Horizon Pharma plc announced that the FDA has approved the label expansion for Procysbi (cysteamine bitartrate) delayed-release capsules. The label will include children aged one year and above suffering from nephropathic cystinosis.
Procysbi is a delayed-release form of cysteamine bitartrate that works by continuously reducing the toxic concentration of cystine in the cells. It plays an important role in managing nephropathic cystinosis and is already approved for both the adults and minors as young as two year-olds.
Horizon’s shares have underperformed the industry year to date. The stock has declined 7.2% against the industry’s growth of 3.5%.
The company’s receipt of the approval for Procysbi’slabel expansion was based on a study that enrolled 17 patients living with nephropathic cystinosis including 15 kids aged between one and five years, previously not treated with cysteamine therapy. The children experienced low white blood cell (WBC) cystine levels varying from poorly to well controlled stages at 12 and 18-month measurements. WBC levels are the biomarker for disease control. . Also a marked improvement was noticed in their weight and height. The study was performed per the FDA’s requirement as a post-marketing commitment after Procysbi was approved.
The Procysbi prescribing information now contains an amended guidance for physicians administering the medicine to pediatric patients.
We remind investors that the ex-U.S. right to Procysbi was divested by Horizon. In May, the company had signed an agreement with Chiesi Farmaceutici S.p.A. to sell its European subsidiary — owning the marketing rights to Procysbi delayed-release capsules — and Quinsair (levofloxacin inhalation solution) in Europe, the Middle East and Africa (EMEA) regions.
Notably, both Procysbi and Quinsair were added in Horizon’s portfolio courtesy of the acquisition of Raptor Pharmaceutical Corp. in October 2016. This strategic transaction happened to strengthen Horizon’s orphan business in the United States and expand its footprint in Europe as well as in other key international markets.
However, following an evaluation of the commercial infrastructure, needed to make Procysbi and Quinsair available across the EMEA belt, the company decided to divest the rights in Europe.
Horizon Pharma PLC Price
Horizon Pharma PLC Price | Horizon Pharma PLC Quote
Zacks Rank & Stocks to Consider
Horizon carries a Zacks Rank #3 (Hold). Some better-ranked health care stocks in the same space are Sucampo Pharmaceuticals , Achillion Pharmaceuticals, Inc. and Corcept Therapeutics Incorporated (CORT - Free Report) , all carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Sucampo’s earnings per share estimates have moved up from 31 cents to $1.12 for 2017 and from $1.15 to $1.19 for 2018 in the last 30 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 15.63%. Share price of the company has surged 32.6% year to date.
Achillionhas seen the Zacks Consensus Estimate of current-year loss per share being narrowed from 65 cents to 63 cents and from 74 cents to 67 cents for 2018 in the last 60 days. The company came up with positive earnings surprises in two of the last four quarters with an average beat of 4.51%.
Corcept’s earnings per share estimates have been revised upward from 78 cents to 88 cents for 2018 in the last 60 days. The company pulled off positive earnings surprises in two of the trailing four quarters with an average beat of 14.32%. Shares of the company have skyrocketed 142.7% year to date.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>